Hemotrial Un proyecto de SEHH

Ensayo clínico

A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoietin receptor agonist, in previously treated pediatric patients with chronic idiopathic thrombocytopenic purpura (ITP).Eltrombopag PETIT: Eltrombopag in PEdiatric patients with Thrombocytopenia from ITPEstudio abierto, doble ciego, aleatorizado, controlado con placebo, de cohortes escalonadas , con tres partes para investigar la eficacia, seguridad, tolerabilidad y farmacocinética de eltrombopag, un agonista del receptor de trombopoyetina, en pacientes pediátricos con púrpura trombocitopénica idiopática (PTI) crónica previamente tratados.Eltrombopag PETIT: Eltrombopag en pacientes pediátricos con trombocitopenia por PTI (Eltrombopag in PEdiatric patients with Thrombocytopenia from ITP)

  • Guardar

  • Imprimir
  • << Volver

Resumen

2017-03-15 04:00:00
2006-002946-13
TRA108062
Descargar
A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoietin receptor agonist, in previously treated pediatric patients with chronic idiopathic thrombocytopenic purpura (ITP).Eltrombopag PETIT: Eltrombopag in PEdiatric patients with Thrombocytopenia from ITPEstudio abierto, doble ciego, aleatorizado, controlado con placebo, de cohortes escalonadas , con tres partes para investigar la eficacia, seguridad, tolerabilidad y farmacocinética de eltrombopag, un agonista del receptor de trombopoyetina, en pacientes pediátricos con púrpura trombocitopénica idiopática (PTI) crónica previamente tratados.Eltrombopag PETIT: Eltrombopag en pacientes pediátricos con trombocitopenia por PTI (Eltrombopag in PEdiatric patients with Thrombocytopenia from ITP)
PETIT
TRA108062

PROMOTORES DEL ENSAYO
Nombre del promotor Organización Persona de contacto País
GlaxoSmithKline S.A. Spain

Fármacos

  INFORMACIÓN DE FÁRMACOS USADOS:
  FÁRMACO 1:
Test
Eltrombopag
SB-497115 Film-coated tablet
Oral use

Detalles del Fármaco (Principio Activo):

SB-497115

Concentración del fármaco:

mg/g milligram( equal

12.5

Contenido del fármaco


Si
No

No
Information no disponible en EudraCT

No
No

No
No

Information no disponible en EudraCT
No

No
No

Si
  FÁRMACO 2:
Test
Eltrombopag
SB-497115 Film-coated tablet
Oral use

Detalles del Fármaco (Principio Activo):

SB-497115

Concentración del fármaco:

mg/g milligram( equal

25

Contenido del fármaco


Si
No

No
Information no disponible en EudraCT

No
No

No
No

Information no disponible en EudraCT
No

No
No

Si
  FÁRMACO 3:
Test
Eltrombopag
SB-497115 Film-coated tablet
Oral use

Detalles del Fármaco (Principio Activo):

SB-497115

Concentración del fármaco:

mg/g milligram( equal

50

Contenido del fármaco


Si
No

No
Information no disponible en EudraCT

No
No

No
No

Information no disponible en EudraCT
No

No
No

Si
  FÁRMACO 4:
Test
Eltrombopag
SB-497115 Film-coated tablet
Oral use

Detalles del Fármaco (Principio Activo):

SB-497115

Concentración del fármaco:

mg/g milligram( equal

75

Contenido del fármaco


Si
No

No
Information no disponible en EudraCT

No
No

No
No

Information no disponible en EudraCT
No

No
No

Si
  INFORMACIÓN DE PLACEBOS USADOS:
  PLACEBO 1:

Si
Film-coated tablet

Oral use

Información General



Trombopenia

Chronic Idiopathic Thrombocytopenic PurpuraPúrpura Trombocitopénica Idiopática Crónica


To assess the efficacy of eltrombopag, relative to placebo, in achieving a platelet count ?50Gi/L at any time during a 6 week treatment period when administered to previously treated pediatric subjects with chronic ITP.

?To describe the safety and tolerability of eltrombopag when administered for 24 weeks?To characterize the PK profile of eltrombopag in pediatric subjects?To describe the efficacy of eltrombopag in achieving platelet counts ? 50Gi/L when administered for 24 weeks?To describe the effect of eltrombopag on reduction and/or interruption of concomitant ITP therapies, when administered for 24 weeks?To describe the effect of eltrombopag on the need for rescue ITP medication when administered to previously treated pediatric subjects?To assess the impact of eltrombopag on the incidence and severity of bleeding symptoms when administered in previously treated pediatric patients?To evaluate the impact of eltrombopag on the quality of life of previously treated pediatric patients

No


1. Subjects between 1 year and <18 years of age at Day 1.2. Written informed consent from subject?s guardian and accompanying informed assent from subject (for children over 6 years old).3. Confirmed diagnosis of chronic ITP, according to the American Society of Hematology / British Committee for Standards in Haematology (ASH/BCSH) guidelines [George, 1996; BCSH, 2003]. In addition, a peripheral blood smear or bone marrow examination should support the diagnosis of ITP with no evidence of other causes of thrombocytopenia.4. Subjects who are refractory or have relapsed after at least one prior ITP therapy or are not eligible, for a medical reason, for other treatments.5. Day 1 (or within 48 hours prior) platelet count <30 Gi/L.6. Previous therapy for ITP with immunoglobulins (IVIg and anti-D) must have been completed at least 2 weeks prior to Day 1 or have been clearly ineffective.7. Subjects treated with concomitant ITP medication (e.g. corticosteroids or azathioprine) must be receiving a dose that has been stable for at least 4 weeks prior to Day 1.8. Previous treatment for ITP with splenectomy, rituximab and cyclophosphamide must have been completed at least 4 weeks prior to Day 1 or have clearly been ineffective.9. Subjects must have prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT) within 80 to 120% of the normal range.10. Subjects must have a complete blood count (CBC) not suggestive of another hematological disorder.11. The following clinical chemistries for the subjects MUST NOT exceed the upper limit of normal (ULN) reference range by more than 20%: creatinine, ALT, AST, total bilirubin, and alkaline phosphatase. In addition, total albumin must not be below the lower limit of normal (LLN) by more than 10%.12. For subjects of child-bearing potential (after menarche): subject must not be sexually active or is practicing an acceptable method of contraception (documented in chart). Female subjects (or female partners of male subjects) must use one of the following highly effective methods of contraception (i.e., Pearl Index <1.0%) from two weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:? Complete abstinence from intercourse;? Intrauterine device (IUD);? Two forms of barrier contraception (diaphragm plus spermicide, and for males condom plus spermicide);? Systemic contraceptives (combined or progesterone only).

1. Any clinically relevant abnormality, other than ITP, identified on the screening examination or any other medical condition or circumstance, which in the opinion of the investigator makes the subject unsuitable for participation in the study or suggests another primary diagnosis (e.g. thrombocytopenia is secondary to another disease).2. Concurrent or past malignant disease, including myeloproliferative disorder.3. Subjects who are not suitable for continuation of their current therapy for at least 7 additional weeks.4. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding Day 1.5. History of platelet agglutination abnormality that prevents reliable measurement of platelet counts.6. Diagnosis of secondary immune thrombocytopenia, including those with laboratory or clinical evidence of HIV infection, anti-phospholipid antibody syndrome, chronic hepatitis B infection, hepatitis C virus infection, or any evidence of active hepatitis at the time of subject screening.7. Subject with Evans syndrome (autoimmune thrombocytopenia and autoimmune hemolysis).8. Subjects with known inherited thrombocytopenia (e.g. MYH-9 disorders)9. Subjects treated with drugs that affect platelet function (including but not limited to aspirin, clopidogrel and/or NSAIDs) or anti-coagulants for >3 consecutive days within 2 weeks of Day 1.10. Subjects who have previously received eltrombopag or any other thrombopoietin receptor agonist.11. For female subjects who have reached menarche status, an inability or unwillingness to provide a blood or urine specimen for pregnancy testing.12. Female subjects who are pregnant or lactating.13. In France, a subject is neither affiliated with nor a beneficiary of a social security category.

Proportion of subjects achieving platelet counts ?50Gi/L at least once between days 8 and 43 of the randomized period of the study.Proporción de sujetos que logren un recuento de plaquetas ? 50 Gi/l al menos en una ocasión entre los días 8 y 43 del período aleatorizado del estudio

Fase II
  DISEÑO DEL ENSAYO:

Si
Si

No
No

Si
Si

No
No
  COMPARADOR DEL ENSAYO CONTROLADO:

No
Si

No
No

Si

Centros participantes:


Si
Information no disponible en EudraCT
  TIEMPO ESTIMADO DURACIÓN DEL ENSAYO:

3
0
  TIEMPO ESTIMADO DURACIÓN DEL ENSAYO EN ESPAÑA:


  POBLACIÓN DE PACIENTES EN EL ESTUDIO:
  Población de pacientes: 1

Rango de edad:


1
0

0

Sexo:


1
1

Número planeado de pacientes a incluir:


6

Para estudios internacionales:


15
15

Investigadores

  INVESTIGADORES QUE PARTICIPAN EN EL ESTUDIO

Estado actual


Por Determinar



En Marcha

Inicial